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Abstract 
Deep insight on Guidance for reporting the 
interpretation of cytogenomic test results in 
haematological neoplasms 
Relationship of any abnormalities 
found to the referral reason 
The report should include a description of the 
abnormality identified and the results should be 
interpreted with respect to the referral reason, or any 
subsequent information received regarding the 
patient (e.g. information subsequently 
communicated by referring clinician). For 
haematological samples the final diagnosis may or 
may not be known at time of sample collection and 
consequently the referral reason can be a confirmed 
diagnosis, a presumptive diagnosis, a differential 
diagnosis or a description of clinical symptoms or 
findings.  
- Where a diagnosis is confirmed, the report should 
state whether the result is consistent with this 
diagnosis. It is unhelpful to discuss the association of 
the abnormality with other disease entities as it may 
bring the diagnosis into question. 
- Where the diagnosis is unconfirmed the report 
should state whether the result supports the 
proposed/presumptive diagnosis. When there is a 
differential diagnosis the report should discuss the 
result in relation to the different neoplasms 
considered. 
- Where no specific diagnosis has been stated on the 
referral card, and only clinical information has been 
provided, it is advised to contact the clinician or the 
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pathology/haematology laboratory for more 
information before reporting. However, when this is 
not possible, the report should provide information 
on its association with specific disease entities. 
- In some cases an abnormality may be identified that 
is inconsistent with the referral reason. It is known 
that some patients with a haematological malignancy 
have a second haematological neoplasm and it is not 
unusual in these cases to identify an abnormal clone 
containing recurrent abnormalities associated with 
one or both neoplasms. For example, in a patient 
referred for CLL, a clone with a deletion 20q may be 
detected. In such cases it is advised to contact the 
clinician for further information before reporting. 
However, when this is not possible, the report should 
state that the abnormality detected neither supports 
nor excludes the diagnosis indicated on the referral 
form and should provide information of any 
association with other specific disease entities. As a 
further example, in a patient referred for CLL, two 
independent clones may be detected, one with a 
trisomy 12 and one with a monosomy 7. Information 
pertaining to both abnormalities should be provided 
on the report. 
- In some cases the abnormality detected may be 
suspected to have a constitutional rather than 
acquired origin and this should be discussed in the 
report. Depending on the nature of the abnormality, 
and considering any reproductive implications for 
the patient’s extended family, confirmation of the 
patient’s constitutional cytogenomic testing can be 
suggested. 
- The most recent WHO (currently 2017) 
nomenclature should be used in relation to the 
disease category, where appropriate. 
Reporting normal results 
The probability of detecting an abnormality depends 
on the pathology and methodology used. 
Laboratories should ensure that the most appropriate 
testing strategy is undertaken. Interpretation of 
normal test results needs careful consideration.  
- Where an abnormal clone cannot be excluded, for 
example where insufficient metaphases have been 
obtained or cell enrichment is not optimal (such as 
low purity of CD138+), the report should include a 
statement to this effect. In addition, appropriate 
additional testing should be recommended in the 
report if not already undertaken. 
Where a prognostic test is performed the report 
should clearly state that no high risk/ adverse 
prognostic factors were detected. 
Reporting complex results  
Reporting complex test results can be challenging 
and it is important that the information provided is 
succinct and clear to the reader of the report.  
The report should summarise the main diagnostic or 
prognostic abnormalities in a clear statement or in 
tabular form, if possible near the beginning of the 
report.  
- It should be clear which pertinent prognostic 
factors have been tested and the report should state 
whether high risk or established abnormalites have 
been detected or not detected (for example TP53 
deletion or mutation not detected). 
- The complex nature of the test result should be 
highlighted although a full description of all the 
abnormalities is not required. If included these 
should be listed elsewhere in the report so as not to 
detract from the major findings. 
- Some pathologies, such as multiple myeloma, 
demonstrate high intraclonal variability and the 
FISH signal patterns observed can be very 
heterogeneous. It is recognised that such cases can 
be difficult to report and therefore complex signal 
patterns do not need to be described in detail. 
However, the report should state an atypical 
heterogeneous signal pattern was detected showing 
gene rearrangement, gain, loss or amplification.  
Prognostic and predictive 
information  
It is good practice to include prognostic and 
predictive information in the report. However, it is 
recognised that local policy and national 
recommendations need be taken into account when 
deciding whether to include this information in the 
report. For example, inclusion of this information 
may not be required when it will be summarised in 
an integrated multidisciplinary report or inclusion 
may be unhelpful in cases where the report is given 
directly to the patient. In the latter case, information 
regarding prognosis should be reported with caution 
as there are always exceptions on a patient level: e.g. 
cases with CLL and TP53 aberrations that do 
perform well, etc. Similarly, inclusion of predictive 
response to therapy in the report can be unhelpful as 
choice of adequate therapeutic option by the 
clinician needs to take into account the patients co-
morbidities and other clinical issues. Where 
laboratory policy is not to include this information in 
the report the laboratory may choose to make this 
information, and any new predicitive data, available 
to the clinician outside the report (telephone, extra 
fact sheet, link to laboratory website, separate 
appendix). 
Where prognostic information is included or has 
been specifically requested a prognostic statement 
must be provided.  
- When no informative prognostic genetic bio-
markers have been identified this should be stated.  
- Where the prognostic information is currently 
contentious this should be highlighted and 
referenced in the report.  
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- Where the abnormality is a predictive marker for 
response to therapy it is recommended to mention 
it in the report.  
- Prognostic information provided should relate to 
robust data from multiple publications/international 
trials/trial protocols or widely accepted prognostic 
systems exists (e.g. IPSS-R in MDS, ELN 
recommendations and MRC prognostic system in 
AML), or evidence from large randomised control  
trials of patients undergoing similar relevant 
treatment or meta-analysis/systematic review of 
multiple studies.  
- Multiple concordant studies can be used and should 
be referenced.  
- Small and isolated studies should not be used to 
derive prognosis although this information can be 
given in the report if put in context and referenced.  
- It should be noted that the prognostic impact of a 
distinct marker relates to the specific treatment 
regimen used in the respective study, e.g. prognosis 
of APL with t(15;17)(q24;q21) is only favourable if 
treatment protocols including ATRA and/or arsenic 
trioxide are used.  
- Cytogenomic results are just one component of 
establishing the patients overall prognosis. For some 
diseases a combined scoring system is used to 
establish risk that incorporates risk scores from 
multiple different tests. For these neoplasms it is 
recommended to state the cytogenetic risk score in 
the report to avoid any confusion with the overall 
risk score which may be different.  
Recommendations 
Where additional testing, not already undertaken, is 
required to clarify the significance of the results this 
should be stated on the report.  
Follow up testing 
The interpretation of follow up testing must relate 
the current results to the previous test results and the 
previous test reference number and sample date 
should be provided in the report.  
Technical reports and provisional 
reports for discussion at multi 
discipline meetings 
In some circumstances a provisional or abbreviated 
report is issued prior to discussion at a multi-
disciplinary team meeting (MDT) or before the 
results of other ongoing testing are available. If a 
purely technical report is issued it should be made 
clear that the interpretation of the results will be 
incorporated into a final integrated report.  
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